{"name":"Synermore Biologics Co., Ltd.","slug":"synermore-biologics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"RabAvert","genericName":"RabAvert","slug":"rabavert","indication":"Other","status":"marketed"},{"name":"SYN004","genericName":"SYN004","slug":"syn004","indication":"Other","status":"phase_1"},{"name":"Imovax","genericName":"Imovax","slug":"imovax","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Adalimumab European source","genericName":"Adalimumab European source","slug":"adalimumab-european-source","indication":"Rheumatoid Arthritis","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SYN023","genericName":"SYN023","slug":"syn023","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"RabAvert","genericName":"RabAvert","slug":"rabavert","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SYN004","genericName":"SYN004","slug":"syn004","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adalimumab European source","genericName":"Adalimumab European source","slug":"adalimumab-european-source","phase":"phase_1","mechanism":"Tumour necrosis factor-alpha inhibitor","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"Imovax","genericName":"Imovax","slug":"imovax","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SYN023","genericName":"SYN023","slug":"syn023","phase":"phase_3","mechanism":"SYN023 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNC1lbGZmZUw1QXpCOUotam52cDloS3RwbnhUWnBlN2JrTUVUMUw5enJEZjVLYmNaeEdid2tYQUgtSEZNSWZpc0Y4QVViSnY4WmNWZ0lKRC1kUzZiRUdGSXJyc3BWTEo1UzRyZERSOXF5YmVNOW81aWZHc1ZxaGd0Sw?oc=5","date":"2026-01-04","type":"patent","source":"Insightace Analytic","summary":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035 - Insightace Analytic","headline":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQYjNrb1ZmNkxHdmlkS1RNZjJ6Q0VtT1d1d1ZMUXN6alNnOUVjM0s1bHFWWURZSFJHckxjWXJ0eU85UG9YVHBXTVBFUkFCQjFHSUFTam5VRWxwLVp2WFlJRzFmdTFnSFZJU0NTbk5idmttXy1faVJRU3lVOUNqWGVXWTJ3?oc=5","date":"2025-06-25","type":"patent","source":"Insightace Analytic","summary":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034. - Insightace Analytic","headline":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOSERqOXo3RmVqLWUzVzZROGdjeDdMWUJFRDFndFFuUEVKZVB1ZUFyN0trS3Q2ZkJZVC1BamQtdTBHYzlacGRqVTZIMC1tX04zc1NXV21URmlNSHlPMjMwYkozMHdacFVsNnljVURabG43YWo0bGdOSUlaNmVpZGVYWk5zZzREUDVSNFNaVVBodnQtSEdBLWRBRUNUM2ZzUldVUl85cGw2S0daYk9oLUFUQXFqdWJmdGh0d1JkTzh3anZORm5wMk5oZU55ZE5PN2FWYnBiQThGUW9waE10amtuSXMyQkYzaTdvckl3dHVQUERITlJzVmxKMnpNSDB4M1lpZ212cWQ1T3JVR2l6YVo1U3lLS3I?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNaXpTSm1oUmI0UHJMaFVteVNtOXNJd0Zadm03Q0VKbHFmcG50R2hzcW9JV2VUOXNGdFFrTXJBWWQ0Q0VPUzRteDBMM184djRsUnE2cVQwM3BfSmhtLUo4bEVKcERlX3U2ekhLQU1Za2RTN3hPdzlXcnNpUUR3QjlSOGxtVFl2LWhqaFJDN2U0N09vbDVNYjlKODBXUDNHQi1idm80VzVB?oc=5","date":"2024-05-24","type":"patent","source":"BioWorld News","summary":"Celltrion’s Omlyclo gets nod as Europe’s first Xolair biosimilar - BioWorld News","headline":"Celltrion’s Omlyclo gets nod as Europe’s first Xolair biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPR18tMm9Mb3J0TDVOZjVlNjQtbHRMblhraGpQZ1FKeWlqMDQ2SDJtbGE5V2puQVVMRExiazk5b1BYM2xpZ3dfTWlfcWp1YXJxUUc3MHRuOExUcGlfMy1QR21JR1Ffb2FSS1lYOXNZUDhiWG5OcGJUNmluRWVEM1kwbUt0UzZwNzZxM1VhUEw3OVkyWlRGV1RoQkZhQzhCTWVLVDlNUUhkTV9PdnFIZk9TLV9VY0NUaDVGLURBVk5QMGZHcmVFYXdWTU5KbTZ6OV9oUHduZ1dWTjN0S255Vnc2WTNNcGM?oc=5","date":"2024-04-08","type":"pipeline","source":"PR Newswire","summary":"Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight - PR Newswire","headline":"Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"PR Newswire","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - PR Newswire","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_1":2,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}